OKYO Pharma Limited
NASDAQ:OKYO · NASDAQ Capital Market
-$0.03 today
Vol 0.05M · Avg 0.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
84.8%
avg 34.3%
ROIC
76.5%
avg -5397155.2%
ROA
-128.0%
avg -234.3%
Analysis
ROE is currently the strongest return metric at 84.8% versus its period average of 34.3%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert J. Dempsey | Chief Executive Officer & Executive Director | $450,000.00 | — | — | $0.00 | <0.01% |
Gary S. Jacob | Chief Development Officer & Director | $450,000.00 | — | 79 | $0.00 | <0.01% |
Rajkumar Patil | Chief Scientific Officer | — | — | 67 | — | — |
Michael Paul Beck | Founder | — | — | 69 | — | — |
Keeren Shah | Chief Financial Officer | — | — | 50 | $0.00 | <0.01% |
Flavio Mantelli | Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Sol-Gel Technologies Ltd.
NASDAQ:SLGL
$206.36M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Tiziana Life Sciences Ltd
NASDAQ:TLSA
$65.37M
Clene Inc.
NASDAQ:CLNN
$60.20M
Anebulo Pharmaceuticals, Inc.
ANEB
$19.37M
Who manages OKYO?
OKYO Pharma Limited (OKYO) lists 6 active executives. The top listed executive is Rajkumar Patil, Chief Scientific Officer.
Are OKYO insiders buying or selling?
Recent insider activity shows net selling of $1.60M.
Explore More
Continue the stock analysis
Jump to another research area for this company.